110 related articles for article (PubMed ID: 27196751)
1. Activating Transcription Factor 3 Expression as a Marker of Response to the Histone Deacetylase Inhibitor Pracinostat.
Sooraj D; Xu D; Cain JE; Gold DP; Williams BR
Mol Cancer Ther; 2016 Jul; 15(7):1726-39. PubMed ID: 27196751
[TBL] [Abstract][Full Text] [Related]
2. ATF3 Repression of BCL-X
Chüeh AC; Tse JWT; Dickinson M; Ioannidis P; Jenkins L; Togel L; Tan B; Luk I; Davalos-Salas M; Nightingale R; Thompson MR; Williams BRG; Lessene G; Lee EF; Fairlie WD; Dhillon AS; Mariadason JM
Clin Cancer Res; 2017 Sep; 23(18):5573-5584. PubMed ID: 28611196
[No Abstract] [Full Text] [Related]
3. A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells.
Toriyama S; Horinaka M; Yasuda S; Taniguchi T; Aono Y; Takamura T; Morioka Y; Miki T; Ukimura O; Sakai T
Mol Cancer Ther; 2016 Sep; 15(9):2066-75. PubMed ID: 27406983
[TBL] [Abstract][Full Text] [Related]
4. Activating transcription factor 3 interferes with p21 activation in histone deacetylase inhibitor-induced growth inhibition of epidermoid carcinoma cells.
Hao ZF; Su YM; Wang CM; Yang RY
Tumour Biol; 2015 Mar; 36(3):1471-6. PubMed ID: 25371069
[TBL] [Abstract][Full Text] [Related]
5. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
[TBL] [Abstract][Full Text] [Related]
6. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways.
Hrgovic I; Doll M; Kleemann J; Wang XF; Zoeller N; Pinter A; Kippenberger S; Kaufmann R; Meissner M
BMC Cancer; 2016 Sep; 16(1):763. PubMed ID: 27716272
[TBL] [Abstract][Full Text] [Related]
7. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
Tung B; Ma D; Wang S; Oyinlade O; Laterra J; Ying M; Lv SQ; Wei S; Xia S
BMC Cancer; 2018 Oct; 18(1):1025. PubMed ID: 30348136
[TBL] [Abstract][Full Text] [Related]
8. ATF3 Coordinates Antitumor Synergy between Epigenetic Drugs and Protein Disulfide Isomerase Inhibitors.
Duncan RM; Reyes L; Moats K; Robinson RM; Murphy SA; Kaur B; Stessman HAF; Dolloff NG
Cancer Res; 2020 Aug; 80(16):3279-3291. PubMed ID: 32561529
[TBL] [Abstract][Full Text] [Related]
9. Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors.
Mensah AA; Spriano F; Sartori G; Priebe V; Cascione L; Gaudio E; Tarantelli C; Civanelli E; Aresu L; Rinaldi A; Damia G; Lovati E; Zucca E; Stathis A; Pietra C; Bertoni F
Blood Adv; 2021 May; 5(10):2467-2480. PubMed ID: 33999145
[TBL] [Abstract][Full Text] [Related]
10. ATF3 suppresses metastasis of bladder cancer by regulating gelsolin-mediated remodeling of the actin cytoskeleton.
Yuan X; Yu L; Li J; Xie G; Rong T; Zhang L; Chen J; Meng Q; Irving AT; Wang D; Williams ED; Liu JP; Sadler AJ; Williams BR; Shen L; Xu D
Cancer Res; 2013 Jun; 73(12):3625-37. PubMed ID: 23536558
[TBL] [Abstract][Full Text] [Related]
11. The novel histone deacetylase inhibitor pracinostat suppresses the malignant phenotype in human glioma.
Chen M; Zhang L; Zhan R; Zheng X
Mol Biol Rep; 2022 Aug; 49(8):7507-7519. PubMed ID: 35622308
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
Salvador MA; Wicinski J; Cabaud O; Toiron Y; Finetti P; Josselin E; Lelièvre H; Kraus-Berthier L; Depil S; Bertucci F; Collette Y; Birnbaum D; Charafe-Jauffret E; Ginestier C
Clin Cancer Res; 2013 Dec; 19(23):6520-31. PubMed ID: 24141629
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.
Ganai SA
Pharm Biol; 2016 Sep; 54(9):1926-35. PubMed ID: 26853619
[TBL] [Abstract][Full Text] [Related]
14. Role of ATF3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic anti-DR5 antibody through ER stress in human colon cancer cells.
Liu J; Edagawa M; Goshima H; Inoue M; Yagita H; Liu Z; Kitajima S
Biochem Biophys Res Commun; 2014 Mar; 445(2):320-6. PubMed ID: 24530917
[TBL] [Abstract][Full Text] [Related]
15. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
16. Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma.
Bayat Mokhtari R; Baluch N; Ka Hon Tsui M; Kumar S; S Homayouni T; Aitken K; Das B; Baruchel S; Yeger H
BMC Cancer; 2017 Feb; 17(1):156. PubMed ID: 28235409
[TBL] [Abstract][Full Text] [Related]
17. Trichostatin A induces bladder cancer cell death via intrinsic apoptosis at the early phase and Sp1‑survivin downregulation at the late phase of treatment.
Wang SC; Wang ST; Liu HT; Wang XY; Wu SC; Chen LC; Liu YW
Oncol Rep; 2017 Sep; 38(3):1587-1596. PubMed ID: 28713892
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Anticancer Activity of Phlorofucofuroeckol A via Upregulation of Activating Transcription Factor 3 against Human Colorectal Cancer Cells.
Eo HJ; Kwon TH; Park GH; Song HM; Lee SJ; Park NH; Jeong JB
Mar Drugs; 2016 Mar; 14(4):. PubMed ID: 27043582
[TBL] [Abstract][Full Text] [Related]
19. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
20. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
